Clinical Trial Update: RC48 in Combination With AK104 and Bevacizumab in OCCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating RC48 in combination with AK104 and bevacizumab for ovarian cancer, including ovarian clear cell carcinoma, is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Clear Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Bevacizumab (bevacizumab)
• RC48 (disitamab vedotin)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Ovary Cancer | Phase 2 | Status: RECRUITING